journal
MENU ▼
Read by QxMD icon Read
search

European Journal of Nuclear Medicine and Molecular Imaging

journal
https://www.readbyqxmd.com/read/28822997/18f-fdg-pet-ct-in-solitary-plasmacytoma-metabolic-behavior-and-progression-to-multiple-myeloma
#1
Domenico Albano, Giovanni Bosio, Giorgio Treglia, Raffaele Giubbini, Francesco Bertagna
PURPOSE: Solitary plasmacytoma (SP) is a rare plasma-cell neoplasm, which can develop both in skeletal and/or soft tissue and frequently progresses to multiple myeloma (MM). Our aim was to study the metabolic behavior of SP and the role of 18F-FDG-PET/CT in predicting progression to MM. MATERIALS AND METHODS: Sixty-two patients with SP who underwent 18F-FDG-PET/CT before any treatment were included. PET images were qualitatively and semiquantitatively analyzed by measuring the maximum standardized uptake value body weight (SUVbw), lean body mass (SUVlbm), body surface area (SUVbsa), metabolic tumor volume (MTV), total lesion glycolysis (TLG) and compared with age, sex, site of primary disease, and tumor size...
August 19, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28821930/quantification-there-is-more-to-worry-about-than-good-scanner-hardware-and-reliable-calibration
#2
EDITORIAL
Jörg Kotzerke, Jörg van den Hoff
No abstract text is available yet for this article.
August 19, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28821924/-89-zr-labeled-nivolumab-for-imaging-of-t-cell-infiltration-in-a-humanized-murine-model-of-lung-cancer
#3
Christopher G England, Dawei Jiang, Emily B Ehlerding, Brian T Rekoske, Paul A Ellison, Reinier Hernandez, Todd E Barnhart, Douglas G McNeel, Peng Huang, Weibo Cai
PURPOSE: Nivolumab is a human monoclonal antibody specific for programmed cell death-1 (PD-1), a negative regulator of T-cell activation and response. Acting as an immune checkpoint inhibitor, nivolumab binds to PD-1 expressed on the surface of many immune cells and prevents ligation by its natural ligands. Nivolumab is only effective in a subset of patients, and there is limited evidence supporting its use for diagnostic, monitoring, or stratification purposes. METHODS: (89)Zr-Df-nivolumab was synthesized to map the biodistribution of PD-1-expressing tumor infiltrating T-cells in vivo using a humanized murine model of lung cancer...
August 19, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28821920/tspo-pet-for-glioma-imaging-using-the-novel-ligand-18-f-ge-180-first-results-in-patients-with-glioblastoma
#4
Nathalie L Albert, M Unterrainer, D F Fleischmann, S Lindner, F Vettermann, A Brunegraf, L Vomacka, M Brendel, V Wenter, C Wetzel, R Rupprecht, J-C Tonn, C Belka, P Bartenstein, M Niyazi
OBJECTIVE: The 18-kDa mitochondrial translocator protein (TSPO) was reported to be upregulated in gliomas. (18)F-GE-180 is a novel 3rd generation TSPO receptor ligand with improved target-to-background contrast compared to previous tracers. In this pilot study, we compared PET imaging with (18)F-GE-180 and MRI of patients with untreated and recurrent pretreated glioblastoma. METHODS: Eleven patients with histologically confirmed IDH wildtype gliomas (10 glioblastomas, 1 anaplastic astrocytoma) underwent (18)F-GE-180 PET at initial diagnosis or recurrence...
August 19, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28821931/targeting-angiogenesis-for-radioimmunotherapy-with-a-177-lu-labeled-antibody
#5
Emily B Ehlerding, Saige Lacognata, Dawei Jiang, Carolina A Ferreira, Shreya Goel, Reinier Hernandez, Justin J Jeffery, Charles P Theuer, Weibo Cai
PURPOSE: Increased angiogenesis is a marker of aggressiveness in many cancers. Targeted radionuclide therapy of these cancers with angiogenesis-targeting agents may curtail this increased blood vessel formation and slow the growth of tumors, both primary and metastatic. CD105, or endoglin, has a primary role in angiogenesis in a number of cancers, making this a widely applicable target for targeted radioimmunotherapy. METHODS: The anti-CD105 antibody, TRC105 (TRACON Pharmaceuticals), was conjugated with DTPA for radiolabeling with (177)Lu (t 1/2 6...
August 18, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28815334/clinical-characteristics-of-patient-selection-and-imaging-predictors-of-outcome-in-solid-tumors-treated-with-checkpoint-inhibitors
#6
REVIEW
Sabrina Rossi, Luca Toschi, Angelo Castello, Fabio Grizzi, Luigi Mansi, Egesta Lopci
The rapidly evolving knowledge on tumor immunology and the continuous implementation of immunotherapy in cancer have recently led to the FDA and EMA approval of several checkpoint inhibitors as immunotherapic agents in clinical practice. Anti-CTLA-4, anti-PD-1, and anti-PDL-1 antibodies are becoming standard of care in advanced melanoma, as well as in relapsed or metastatic lung and kidney cancer, demonstrating higher and longer response compared to standard chemotherapy. These encouraging results have fostered the evaluation of these antibodies either alone or in combination with other therapies in several dozen clinical trials for the treatment of multiple tumor types...
August 16, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28815291/prognostic-value-of-atherosclerotic-burden-and-coronary-vascular-function-in-patients-with-suspected-coronary-artery-disease
#7
Roberta Assante, Wanda Acampa, Emilia Zampella, Parthiban Arumugam, Carmela Nappi, Valeria Gaudieri, Ciro Gabriele Mainolfi, Mariarosaria Panico, Mario Magliulo, Christine M Tonge, Mario Petretta, Alberto Cuocolo
PURPOSE: To evaluate the prognostic value of coronary atherosclerotic burden, assessed by coronary artery calcium (CAC) score, and coronary vascular function, assessed by coronary flow reserve (CFR) in patients with suspected coronary artery disease (CAD). METHODS: We studied 436 patients undergoing hybrid (82)Rb positron emission tomography/computed tomography imaging. CAC score was measured according to the Agatston method, and patients were categorized into three groups (0, <400, and ≥400)...
August 16, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28812136/clinical-outcomes-of-y90-radioembolization-for-recurrent-hepatocellular-carcinoma-following-curative-resection
#8
Rehan Ali, Ahsun Riaz, Ahmed Gabr, Nadine Abouchaleh, Ronald Mora, Ali Al Asadi, Juan Carlos Caicedo, Michael Abecassis, Nitin Katariya, Haripriya Maddur, Laura Kulik, Robert J Lewandowski, Riad Salem
PURPOSE: To assess safety/efficacy of yttrium-90 radioembolization (Y90) in patients with recurrent hepatocellular carcinoma (HCC) following curative surgical resection. METHODS: With IRB approval, we searched our prospectively acquired database for patients that were treated with Y90 for recurrent disease following resection. Baseline characteristics and bilirubin toxicities following Y90 were evaluated. Intention-to-treat overall survival (OS) and time-to-progression (TTP) from Y90 were assessed...
August 15, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28812134/elevated-tumor-to-liver-uptake-ratio-tlr-from-18-f-fdg-pet-ct-predicts-poor-prognosis-in-stage-iia-colorectal-cancer-following-curative-resection
#9
Jun Huang, Liang Huang, Jiaming Zhou, Yinghua Duan, Zhanwen Zhang, Xiaoyan Wang, Pinzhu Huang, Shuyun Tan, Ping Hu, Jianping Wang, Meijin Huang
PURPOSE: The prognostic value of the tumor-to-liver uptake ratio (TLR) from 18-fluoro-2-deoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) in the early stage of colorectal cancer (CRC) is unclear. Notably, some stage IIA CRC patients experience early recurrence even after curative resection and might benefit from neoadjuvant or adjuvant chemotherapy. This study aims to evaluate whether elevated TLR from (18)F-FDG-PET/CT can predict poor prognosis in stage IIA CRC patients undergoing curative resection...
August 15, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28808744/comment-on-comparison-of-ct-and-pet-ct-for-biopsy-guidance-in-oncological-patients
#10
LETTER
Long Chen, Hua Sun
No abstract text is available yet for this article.
August 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28808743/saving-costs-in-cancer-patient-management-through-molecular-imaging
#11
EDITORIAL
Carl von Gall, Piotr Maniawski, Fred Verzijlbergen, Ignasi Carrio, Thomas Beyer, Antonis Kalemis
No abstract text is available yet for this article.
August 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28808732/individualized-risk-assessment-in-neuroblastoma-does-the-tumoral-metabolic-activity-on-123-i-mibg-spect-predict-the-outcome
#12
Julian M M Rogasch, Patrick Hundsdoerfer, Christian Furth, Florian Wedel, Frank Hofheinz, Paul-Christian Krüger, Holger Lode, Winfried Brenner, Angelika Eggert, Holger Amthauer, Imke Schatka
PURPOSE: Risk-adapted treatment in children with neuroblastoma (NB) is based on clinical and genetic factors. This study evaluated the metabolic tumour volume (MTV) and its asphericity (ASP) in pretherapeutic (123)I-MIBG SPECT for individualized image-based prediction of outcome. METHODS: This retrospective study included 23 children (11 girls, 12 boys; median age 1.8 years, range 0.3-6.8 years) with newly diagnosed NB consecutively examined with pretherapeutic (123)I-MIBG SPECT...
August 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28803435/a-kinetic-solution-for-the-paradoxical-difference-between-f-dopa-and-methionine
#13
LETTER
Masashi Kameyama, Yumi Umeda-Kameyama
No abstract text is available yet for this article.
August 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28803358/prospective-head-to-head-comparison-of-11-c-choline-pet-mr-and-11-c-choline-pet-ct-for-restaging-of-biochemical-recurrent-prostate-cancer
#14
Matthias Eiber, Isabel Rauscher, Michael Souvatzoglou, Tobias Maurer, Markus Schwaiger, Konstantin Holzapfel, Ambros J Beer
PURPOSE: Whole-body integrated (11)C-choline PET/MR might provide advantages compared to (11)C-choline PET/CT for restaging of prostate cancer (PC) due to the high soft-tissue contrast and the use of multiparametric MRI, especially for detection of local recurrence and bone metastases. MATERIALS AND METHODS: Ninety-four patients with recurrent PC underwent a single-injection/dual-imaging protocol with contrast-enhanced PET/CT followed by fully diagnostic PET/MR...
August 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28801787/reduction-of-68-ga-psma-renal-uptake-with-mannitol-infusion-preliminary-results
#15
Federica Matteucci, Emilio Mezzenga, Paola Caroli, Valentina Di Iorio, Anna Sarnelli, Monica Celli, Lorenzo Fantini, Andrea Moretti, Riccardo Galassi, Ugo De Giorgi, Giovanni Paganelli
PURPOSE: Urea-based prostate-specific membrane antigen (PSMA) ligands labelled with (68)Ga or (177)Lu are new tracers with great potential for theranostic approaches in prostate cancer. However, clinical studies have shown that the kidneys are one of the off-target organs along with the salivary and lacrimal glands. In the kidneys, PSMA is physiologically expressed in the apical epithelium of the proximal tubules, and mannitol acts as an osmotic diuretic in these tubules. We investigated the potential of mannitol to reduce renal uptake of (68)Ga-PSMA...
August 11, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28801744/the-relevance-of-data-driven-motion-correction-in-diagnostic-pet
#16
LETTER
Adam Leon Kesner
No abstract text is available yet for this article.
August 11, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28785843/18f-fdg-pet-diagnostic-and-prognostic-patterns-do-not-overlap-in-alzheimer-s-disease-ad-patients-at-the-mild-cognitive-impairment-mci-stage
#17
Silvia Morbelli, Matteo Bauckneht, Dario Arnaldi, Agnese Picco, Matteo Pardini, Andrea Brugnolo, Ambra Buschiazzo, Marco Pagani, Nicola Girtler, Alberto Nieri, Andrea Chincarini, Fabrizio De Carli, Gianmario Sambuceti, Flavio Nobili
PURPOSE: We aimed to identify the cortical regions where hypometabolism can predict the speed of conversion to dementia in mild cognitive impairment due to Alzheimer's disease (MCI-AD). METHODS: We selected from the clinical database of our tertiary center memory clinic, eighty-two consecutive MCI-AD that underwent 18F-fluorodeoxyglucose (FDG) PET at baseline during the first diagnostic work-up and were followed up at least until their clinical conversion to AD dementia...
August 7, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28785842/metabolic-tumor-burden-quantified-on-18-f-fdg-pet-ct-improves-tnm-staging-of-lung-cancer-patients
#18
Paula Lapa, Bárbara Oliveiros, Margarida Marques, Jorge Isidoro, Filipe Caseiro Alves, J M Nascimento Costa, Gracinda Costa, João Pedroso de Lima
PURPOSE: The purpose of our study was to test a new staging algorithm, combining clinical TNM staging (cTNM) with whole-body metabolic active tumor volume (MATV-WB), with the goal of improving prognostic ability and stratification power. METHODS: Initial staging [(18)F]FDG PET/CT of 278 non-small cell lung cancer (NSCLC) patients, performed between January/2011 and April/2016, 74(26.6%) women, 204(73.4%) men; aged 34-88 years (mean ± SD:66 ± 10), was retrospectively evaluated, and MATV-WB was quantified...
August 7, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28782071/about-the-specificity-of-radiotracers-for-prostate-cancer
#19
LETTER
Michael Soussan
No abstract text is available yet for this article.
August 7, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28780722/validation-and-head-to-head-comparison-of-three-nomograms-predicting-probability-of-lymph-node-invasion-of-prostate-cancer-in-patients-undergoing-extended-and-or-sentinel-lymph-node-dissection
#20
Nikolaos Grivas, Esther Wit, Corinne Tillier, Erik van Muilekom, Floris Pos, Alexander Winter, Henk van der Poel
PURPOSE: The updated Winter nomogram is the only nomogram predicting lymph node invasion (LNI) in prostate cancer (PCa) patients based on sentinel node (SN) dissection (sLND). The aim of the study was to externally validate the Winter nomogram and examine its performance in patients undergoing extended pelvic lymph node dissection (ePLND), ePLND combined with SN biopsy (SNB) and sLND only. The results were compared with the Memorial Sloan Kettering Cancer Center (MSKCC) and updated Briganti nomograms...
August 5, 2017: European Journal of Nuclear Medicine and Molecular Imaging
journal
journal
20104
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"